azimexon

01/01/1983 - "After inducing remission in ten patients with metastasizing breast cancer by a combination chemotherapy given for about one year, leucocytes, T- and B-lymphocytes and reactivity of peripheral lymphocytes to different mitogens were determined at weekly intervals before (8 X), during (8 X while on 100 mg i.v. weekly, then 4 X while on 400 mg i.v. weekly) and after (4 X) treatment with AZIMEXONE. "

08/01/1986 - "Azimexon, a synthetic derivative of the 2-cyanaziridines, was given intravenously daily for 5 days to 19 cancer patients in a Phase I trial designed to determine the drug's tolerable dose, toxicity, and effects on immune and nonimmune host defense parameters. "
08/01/1986 - "Azimexon may have a role in managing cancer-associated dysregulation of the immune response."
11/01/1981 - "Effect of BM 12531 on rosette formation and in vitro functions of peripheral blood lymphocytes obtained from healthy donors and cancer patients."
01/01/1980 - "The possible mechanisms of the anergy of the cancer patients and of the mode of action of azimexon are discussed."
01/01/1980 - "Seven of 11 anergic cancer patients have been immunorestored by a relatively low dosage of azimexon. "

01/01/1980 - "Azimexon, a new synthetic immunoadjuvant, can act on delayed-type hypersensitivity (DTH) reactions. "
03/01/1984 - "In particular, the induction of leukocytosis, the stimulation of delayed-type hypersensitivity reactions and the synergistic effect of azimexon and antibiotics in the control of lethal bacterial and fungal infections in mice prompted us to test azimexon as an adjuvant to chemotherapy in 14 myeloma patients. "
01/01/1984 - "The substances D-penicillamine, auranofin, chloroquine, levamisole, BM 41.332, azimexone, bestatin, methisoprinol (inosiplex), thymosine (fraction 5), indomethacin and cyclophosphamide were examined comparatively in the delayed type hypersensitivity test after oxazolone sensitisation in mice. "

06/01/1986 - "In search of potential therapeutic agents for the acquired immunodeficiency syndrome (AIDS) among homosexual males, we studied in vitro the immunorestorative effect of azimexon in patients with this syndrome. "
06/01/1986 - "Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon."
01/01/1986 - "Azimexon, a 2-cyan-aziridinyl immune modulator, was given at a dose of 250 mg/m2/day for 10 days IV to 12 patients with AIDS and 16 with AIDS related complex (ARC). "
01/01/1986 - "Effect of azimexon therapy on host defense parameters and disease-associated symptoms in the acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC)."

01/01/1981 - "Influence of the immunostimulating compound azimexone (2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane) on the number of metastases in the Lewis lung carcinoma in mice."